Figures & data
Figure 1 The Regional Medicines Information and Pharmacovigilance Centres (RELIS) in Norway provide feedback to health care professionals on spontaneous drug-related questions and adverse drug-reaction (ADR) reports published in a question–answer pair (QAP) database (the RELIS database) and the Norwegian ADR database, respectively.
Notes: Mutual use of the two ADR information sources has the potential to increase knowledge of drug safety due to data accumulation. The example of pregabalin and suspicion of drug abuse after the marketing of Lyrica in Norway in September 2004 is used to illustrate RELIS’s potential to detect new drug-safety information through a limited number of QAPs and ADR reports.
